Table 1.
Selected demographic, genetic, clinical, and neuropathologic data on the 13 included cohorts*
| Characteristics | ACT | Brazilian BAS | CC75C | CFAS | Duke/UNC ADRC | HAAS | Mayo/MCSA | Nun study | ROS-MAP | The 90 + study | UKy-ADRC | Vantaa 85 + | VITA | Total or weighted average** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| Country | USA | Brazil | UK | UK | USA | USA | USA | USA | USA | USA | USA | Finland | Austria | |
| Sample size | 863 | 625 | 228 | 510 | 109 | 321 | 209 | 382 | 1620 | 402 | 318 | 302 | 307 | 6196 |
| Average age at death, years | 89.0 | 72.2 | 91.5 | 87.0 | 94.1 | 90.3 | 86.6 | 91.1 | 89.9 | 97.2 | 88.4 | 92.4 | 83.2 | 88.1** |
| % Female | 59.4 | 48.7 | 70.6 | 60.4 | 67.0 | 0 | 40.0 | 100 | 69.2 | 69.7 | 63.2 | 83.1 | 58.6 | 62.3%** |
| # Known APOE status | 831 | 306 | 216 | 289 | 109 | 303 | 209 | 369 | 1554 | 371 | 318 | 282 | 0 | 5157 |
| % APOE ε4 allele | 27.4 | 13.0 | 32.5 | 29.0 | 27.6 | 21.8 | 24.9 | 23.0 | 24.9 | 20.8 | 33.6 | 31.6 | N/A | 25.5%** |
| Final cognitive status | ||||||||||||||
| # clinical normal | 308 | 461 | 63 | 189 | 29 | 139 | 142 | 167 | 529 | 114 | 142 | 107*** | 37 | 2427 |
| # clinical MCI/proxy | 17 | 44 | 39 | 10 | 26 | 68 | 44 | 48 | 372 | 113 | 49 | N/A | 11 | 841 |
| # clinical dementia | 381 | 101 | 113 | 275 | 49 | 97 | 22 | 136 | 718 | 174 | 110 | 195 | 26 | 2397 |
| Neuropathologic features | ||||||||||||||
| % neocortical LBs | 12.9 | 3.4 | 4.8 | 3.7 | 3.9 | 6.2 | 6.2 | 6.9 | 14.2 | 9.2 | 13.2 | 14.2 | 4.1 | 9.5%** |
| % Braak stages 0-II | 25.6 | 67.6 | 17.6 | 36.7 | 12.8 | 49.8 | 41.1 | 44.5 | 15.7 | 7.2 | 43.4 | 17.6 | 59.5 | 31.5%** |
| % Braak stages III-IV | 36.3 | 23.9 | 60.8 | 41.5 | 67.0 | 31.2 | 41.6 | 23.6 | 56.0 | 54.0 | 26.7 | 47.2 | 20.3 | 42.0%** |
| % Braak stages V-VI | 38.1 | 8.5 | 21.6 | 21.9 | 20.2 | 19.0 | 17.2 | 31.9 | 28.3 | 38.8 | 29.9 | 35.2 | 20.3 | 26.5%** |
| % LATE-NC**** | 47.9 | 11.1 | 48.7 | 67.7 | 30.3 | 24.7 | 24.9 | 16.2 | 52.2 | 36.1 | 36.0 | 37.1 | 16.9 | 39.4%** |
ACT adult changes in thought [58], BAS Brazilian biobank for aging studies of the University of Sao Paulo [106], CC75C Cambridge city over-75 s cohort [16], CFAS medical research council cognitive function and ageing study [115], Duke/UNC-ADRC Duke/University of North Carolina AD Research Center [36], HAAS Honolulu Asia-aging study [116], MCSA Mayo Clinic study of aging [91], Nun Study[112], ROS-MAP Rush University Religious Orders Study/Memory and Aging Project [10], The 90 + Study University of California Irvine The 90 + Study [50], UKy-ADRC University of Kentucky AD Research Center [98], Vantaa 85 + Study [52], and VITA Vienna Trans-Danube Aging study [55], APOE apolipoprotein E, MCI mild cognitive impairment, LBs lewy bodies, LATE-NC limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes
See text for more details on data missingness and cohort-specific operationalizations
weighted average
number of subjects with no dementia according to the DSMIIIR criteria
these percentages are for cases with full CERAD neuritic plaque data
see Supplemental Table 3, online resource